Progesterone: Drug-Centric Assessment
This is an example Biotica Bio deliverable: a drug-centric assessment for Progesterone, generated from the Open Targets Platform API and interpreted for repurposing and commercial context. The data below is derived from the Platform’s aggregated sources; the narrative and strategic synthesis are by Biotica Bio.
This assessment is for strategic and due-diligence use only; it does not constitute regulatory, medical, or investment advice.
For methodology, see How it’s built.
Data: Open Targets Platform. Interpretation and narrative: Biotica Bio.
1. Executive summary
- Progesterone is a Small molecule with 47 indication(s) in the Platform; description notes approved and investigational use.
- Current indications: See table below (top 7 of 47); spans reproductive, metabolic, neurological, and other therapeutic areas.
- Mechanism and targets: Mechanism/target detail in Platform; steroid hormone (e.g. progesterone receptor).
- Repurposing angle: Long off-patent; broad indication set supports repurposing and combination narratives (e.g. neuroprotection, TBI, cancer contexts).
- Commercial take: Differentiate via formulation, indication expansion, or biomarker-led development; competitive landscape varies by indication.
2. Drug profile
Progesterone is a Small molecule. Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 3 approved and 44 investigational indications. This drug has a black box warning from the FDA. Trade names: Crinone, Cyclogest, Endometrin, Lutigest, Milprosa (and others).
3. Where the drug is used (indications)
| Indication | Therapeutic area |
|---|---|
| anorexia nervosa | — |
| Osteopenia | — |
| cervical intraepithelial neoplasia | — |
| breast carcinoma | — |
| hemorrhage | — |
| Vulvar Lichen Sclerosus | — |
| bulimia nervosa | — |
Commercial take: Focused indication strategy and repurposing potential; use Platform disease-level data to assess competition per indication.
4. Targets and mechanism
Target and mechanism detail can be explored in the Open Targets Platform (e.g. progesterone receptor for steroid hormones).
5. Repurposing and commercial angle
With 47 indications in the Platform (approved and investigational), Progesterone has broad repurposing potential. Prioritise indications where evidence and unmet need align (e.g. neuroprotection, traumatic brain injury, or specific cancer contexts); use Platform disease and target data to assess competition per indication.
Commercial take: Prioritise indications with strong evidence and manageable competition; leverage off-patent status for formulation and lifecycle strategies.
6. Data provenance and methodology
Report generated from the Open Targets Platform GraphQL API (https://api.platform.opentargets.org/api/v4/graphql). Query: drug-centric assessment (drug by chemblId: identity, mechanismsOfAction, indications, drugWarnings). Drug: Progesterone (CHEMBL103). Re-run fetch-drug.js and generate-drug-report.js for this ChEMBL ID (or another) to refresh the report; interpretation and strategic narrative are by Biotica Bio.
Data: Open Targets Platform. Interpretation and narrative: Biotica Bio. For methodology, see How it’s built.